Comparative analysis of ibalizumab and standard antiretroviral therapy (ART) across key clinical, pharmacological, and practical parameters.
| Parameter | Ibalizumab (Trogarzo) | Standard ART |
|---|---|---|
| Drug class | Monoclonal antibody; CD4 post-attachment inhibitor | Multiple classes: NRTIs, NNRTIs, PIs, InSTIs, fusion inhibitors, CCR5 antagonists |
| Mechanism | Binds CD4 domain 2; sterically blocks post-attachment co-receptor engagement; MHC class II function preserved | Targets viral enzymes (reverse transcriptase, protease, integrase) or viral entry machinery |
| Administration route | Intravenous infusion (intramuscular and subcutaneous routes under investigation) | Primarily oral; long-acting injectable formulations (cabotegravir/rilpivirine) increasingly available |
| Dosing schedule | Loading 2,000 mg IV, then 800 mg IV every 2 weeks; requires clinic attendance | Daily oral tablets; or monthly/bimonthly injections for approved long-acting regimens |
| Approved indication | Multidrug-resistant human immunodeficiency virus-1 (MDR HIV-1) in heavily treatment-experienced adults failing current ART (USA and EU) | HIV-1 treatment across naive and experienced patients (class- and guideline-dependent) |
| Efficacy in MDR HIV-1 | Established; 83% ≥ 0.5 log10 VL reduction at week 24 in pivotal trial | Substantially limited by multi-class pre-existing resistance |
| Resistance profile | V5 glycan loss in gp120; rapid as monotherapy; mitigated by optimised background regimen (OBR) combination | Complex, drug-class-specific mutational pathways; accumulation over years drives MDR phenotype |
| Long-term safety | Favourable short- and medium-term profile; long-term data accumulating | Well characterised over decades; class-specific toxicities documented (renal, cardiovascular, metabolic) |
| Adherence dynamics | Healthcare provider-administered; eliminates patient adherence burden; but requires biweekly clinic visits | Patient-administered; pill burden, frequency, and tolerability drive real-world adherence variability |
| Cost and access | High cost; no generic formulation; limited availability in low- and middle-income countries (LMICs); logistics-intensive | Variable; generic first-line agents widely available in LMICs via donor and government programmes |